Aspergillus fumigatus and pan-azole resistance: who should be concerned?
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Purpose of review: Although clinical outcomes in the treatment of aspergillosis have markedly improved with the availability of newer triazoles, the development of resistance to these antifungals, especially in Aspergillus fumigatus, is a growing concern. The purpose of this review is to provide an update on azole resistance mechanisms and their epidemiology in A. fumigatus, the clinical implications of azole resistance, and to discuss future treatment options against azole-resistant aspergillosis. Recent findings: Resistance may develop through either patient or environmental azole exposure. Environmental exposure is the most prevalent means of resistance development, and these isolates can cause disease in various at-risk groups, which now include those with influenza, and potentially COVID-19. Although current treatment options are limited, newer therapies are in clinical development. These include agents with novel mechanisms of action which have in vitro and in vivo activity against azole-resistant A. fumigatus. Summary: Azole-resistant A. fumigatus is an emerging threat that hampers our ability to successfully treat patients with aspergillosis. Certain geographic regions and patient populations appear to be at increased risk for this pathogen. As new patient groups are increasingly recognized to be at increased risk for invasive aspergillosis, studies to define the epidemiology and management of azole-resistant A. fumigatus are critically needed. While treatment options are currently limited, new agents under clinical development may offer hope.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Schauwvlieghe, A. F. A. D., Rijnders, B. J. A., Philips, N., Verwijs, R., Vanderbeke, L., Van Tienen, C., Lagrou, K., Verweij, P. E., Van de Veerdonk, F. L., Gommers, D., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30274-1 · Cited by 886
Self-citationCOVID-19 Associated Pulmonary Aspergillosis
Koehler, P., Cornely, O. A., Böttiger, B. W., Dusse, F., Eichenauer, D. A., Fuchs, F., Hallek, M., Jung, N., Klein, F., Persigehl, T., et al. (2020) · Mycoses · doi:10.1111/myc.13096 · Cited by 547
Willger, S. D., Puttikamonkul, S., Kim, K.-H., Burritt, J. B., Grahl, N., Metzler, L. J., Barbuch, R., Bard, M., Lawrence, C. B., & Cramer, R. A. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000200 · Cited by 345
van der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit320 · Cited by 342
Self-citationF901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289
Self-citationMellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2747-2750.2004 · Cited by 210
Diagnosing COVID-19-associated pulmonary aspergillosis
Verweij, P. E., Gangneux, J.-P., Bassetti, M., Brüggemann, R. J. M., Cornely, O. A., Koehler, P., Lass-Flörl, C., van de Veerdonk, F. L., Chakrabarti, A., & Hoenigl, M. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30027-6 · Cited by 181 · cited 3×
“Many IAPA patients lack classic risk factors for invasive aspergillosis, and influenza was found to be an independent risk factor for IPA [47 && ].”
BackgroundSelf-citationWatanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00731-11 · Cited by 169 · cited 2×
“This agent is capable of inhibiting inositol acylation in fungi, including Aspergillus species, but not in humans [81].”
BackgroundEnvironmental Hotspots for Azole Resistance Selection of Aspergillus fumigatus , the Netherlands
Schoustra, S. E., Debets, A. J. M., Rijs, A. J. M. M., Zhang, J., Snelders, E., Leendertse, P. C., Melchers, W. J. G., Rietveld, A. G., Zwaan, B. J., & Verweij, P. E. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2507.181625 · Cited by 164 · cited 1×
“fumigatus is a saprobic fungus, it may grow in plant material waste, and resistance selection can occur if azole fungicide residues are present [30].”
BackgroundSelf-citation
Cited by
COVID‐19–associated pulmonary aspergillosis: a prospective single‐center dual case series
Meijer, E. F. J., Dofferhoff, A. S. M., Hoiting, O., & Meis, J. F. (2021) · Mycoses · doi:10.1111/myc.13254 · Cited by 56
Mechanisms of Azole Potentiation: Insights from Drug Repurposing Approaches
Xiong, J., Lu, H., & Jiang, Y. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00657 · Cited by 20
How do I manage refractory invasive pulmonary aspergillosis
Vergidis, P., Sendi, P., Alkhateeb, H. B., & Nguyen, M. H. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.01.015 · Cited by 12
Metadata
- Authors
- Wiederhold, N. P., & Verweij, P. E.
- Venue
- Current Opinion in Infectious Diseases
- Published
- 2020-06-30
- Volume
- 33
- Issue
- 4
- Pages
- 290-297
- ISSN
- 0951-7375 (ISSN-L)
- 1473-6527
- OpenAlex
- W3041616127
- Cited by
- 94
- References
- 22
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aspergillus fumigatus and pan-azole resistance: who should be concerned? https://app.cochat.ai/papers/10.1097/qco.0000000000000662
- The paper
- Wiederhold, N. P., & Verweij, P. E. (2020). Aspergillus fumigatus and pan-azole resistance: who should be concerned? Current Opinion in Infectious Diseases. https://doi.org/10.1097/qco.0000000000000662
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.